Compare CHCI & FOCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCI | FOCL |
|---|---|---|
| Founded | 1985 | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.5M | 222.4M |
| IPO Year | 2004 | 1998 |
| Metric | CHCI | FOCL |
|---|---|---|
| Price | $19.05 | $4.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.80 |
| AVG Volume (30 Days) | 37.4K | ★ 76.1K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | $62,861,000.00 | ★ $70,527,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.10 |
| P/E Ratio | $206.11 | ★ N/A |
| Revenue Growth | ★ 22.55 | 1.63 |
| 52 Week Low | $10.14 | $4.00 |
| 52 Week High | $22.07 | $6.40 |
| Indicator | CHCI | FOCL |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 42.52 |
| Support Level | $17.64 | $4.01 |
| Resistance Level | $19.84 | $4.63 |
| Average True Range (ATR) | 0.86 | 0.28 |
| MACD | -0.22 | -0.01 |
| Stochastic Oscillator | 0.75 | 11.99 |
Comstock Holding Co Inc is a developer and manager of mixed-use and transit-oriented properties with operations that are majorly focused on the Washington, D.C. metropolitan area. It provides a range of services such as asset management, property management, development and construction management, and other real estate-related services to its asset-owning clients, composed predominantly of institutional real estate investors, high net worth family offices, financial institutions, and governmental bodies seeking to enhance their surrounding communities by developing real estate through public-private partnerships.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.